How Ph.D. was paid
$4M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|
| Elisabet de los Pinos, Ph.D.Former President, Chief Executive Officer and Director | $645,483 | $1,492,378 | $1,513,293 | $284,013 | $21,000 | $3,956,167 |
| Anthony GibneyChief Financial and Business Officer | $345,909 | $1,006,915 | $1,209,402 | $189,000 | — | $2,751,226 |
| J. Jill Hopkins, M.D.Chief Medical Officer and President of Research and Development | $551,250 | $926,477 | $469,738 | $220,500 | $21,000 | $2,188,965 |
What changed and why
- 3,956,167 was Elisabet de los Pinos's 2025 total compensation, up from 3,604,339 in 2024.
- 80%80% of corporate performance goals were achieved for 2025.
- 55%55%, 50%, and 45% were the target bonuses for de los Pinos, Hopkins, and Gibney, respectively.
- 2,498,310 was de los Pinos's combined 2025 stock and option award value.
- Anthony Gibney received initial equity grants upon joining as Chief Financial and Business Officer.
- Dr. de los Pinos resigned as CEO and President effective April 30, 2026.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.